METASTATIC BREAST CANCER

This phase 2 study tests the best order of two powerful targeted drugs (sacituzumab govitecan and trastuzumab deruxtecan) in 216 people with HER2-low metastatic breast cancer that has spread. Researchers want to see which sequence works better and find markers that predict respon…

This study looks at whether adding a precise, high-dose radiation treatment called SABR to ongoing hormone therapy and CDK 4/6 inhibitors can delay the need to switch to a new cancer treatment in people with ER-positive, HER2-negative advanced breast cancer. About 74 participants…

This early-stage study looks at whether taking a new oral chemotherapy (paclitaxel) with or without food changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or ovarian cancer) will take the drug after fasting or after a meal, t…

This study tests a new combination of two drugs (JSKN016 and D-0502) in 60 people with advanced hormone receptor-positive, HER2-negative breast cancer that has worsened after standard hormone therapy. The goal is to see if the combo is safe and shrinks tumors. Participants receiv…

This study tests a new drug combination (RC48 plus chemotherapy) against standard treatment (trastuzumab or inetetamab plus chemo) in people with HER2-positive advanced breast cancer whose disease worsened or who couldn't tolerate a prior type of antibody-drug conjugate. About 26…

This study tests a device called TheraBionic P1 in 82 people with advanced or metastatic HR-positive, HER2-negative breast cancer who have already tried standard hormone therapies. The goal is to see if the device can slow cancer growth and improve survival. Participants will use…

This study tests a virtual group lifestyle program for 100 women with stable HR+/HER2- metastatic breast cancer. The goal is to see how much support helps them stick with healthy habits like diet and exercise. It aims to improve well-being and manage symptoms, not cure the diseas…

This study tests an educational program called SHARE-MC designed to help women with metastatic breast cancer address sexual health concerns. Researchers will enroll 96 women who report significant sexual dysfunction. The program aims to improve sexual function and reduce psycholo…

This early study tests the safety of using short electric pulses to destroy soft tissue tumors near the skin in people with metastatic breast cancer. About 20 adults will receive the treatment under image guidance. The main goal is to see if the procedure is safe and to measure a…

This study will review medical records of about 240 adults in Kazakhstan with HER2-positive metastatic breast cancer to understand which treatments doctors use and how well they work. Researchers want to learn how long patients live without their cancer getting worse. This is an …

This study looks at whether a special online tool can help older adults (65+) with metastatic breast cancer and their care partners make better treatment decisions. Researchers will ask 150 participants to use the tool and then rate how acceptable, appropriate, and practical it i…

This study looks at whether a type of PET-CT scan can better detect if the drug trastuzumab deruxtecan (T-DXd) is working in people with HER2 low metastatic breast cancer. The goal is to see if this scan can identify non-responders earlier than standard CT scans, potentially avoi…

This study will test a new artificial intelligence (AI) tool that helps breast cancer patients learn about their condition and treatment. About 35 adults with breast cancer will use the AI to ask questions and get answers. Doctors will check if the information is safe, accurate, …

This study tracks the safety and effectiveness of TUKYSA in 600 adults with HER2-positive advanced or metastatic breast cancer in Korea. Participants will receive TUKYSA as part of their normal care, and researchers will monitor their response and any side effects. The goal is to…

This study looks at whether training doctors in shared decision-making and giving patients educational materials can improve conversations about treatment for HER2-negative metastatic breast cancer. About 120 patients starting their first treatment will join, and their experience…